Know Cancer

forgot password

Propranolol vs Prednisolone for Infant Hemangiomas-A Clinical and Molecular Study

Phase 2
5 Months
Open (Enrolling)
Hemangioma of Infancy

Thank you

Trial Information

Propranolol vs Prednisolone for Infant Hemangiomas-A Clinical and Molecular Study

Infants with symptomatic hemangiomas will be enrolled. Magnetic resonance imaging will be
completed before starting medication if the extent of the hemangioma is not evident on
clinical examination alone. Infants will be randomized to receive either propranolol or
steroids for 4-6 months. Hemangioma response will be measured and compared monthly as will
tolerability of the medications. Additionally, urine specimens will be collected at each
visit to determine if markers are present that can predict response to therapy.

Additionally, any hemangiomas that are excised will be examined for genetic markers to aid
in predicting response to therapy.

Inclusion Criteria:

- infants with symptomatic hemangiomas

Exclusion Criteria:

- asthma

- diabetes

- hypertension

- hypotension

- hypoglycemia

- liver failure

- previous treatment for hemangiomas

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment

Outcome Measure:

reduction in size of hemangioma

Outcome Time Frame:

4-6 months

Safety Issue:


Principal Investigator

Nancy M Bauman, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Children's Research Institute, Children's National Medical Center


United States: Institutional Review Board

Study ID:

IRB 4502



Start Date:

July 2009

Completion Date:

December 2014

Related Keywords:

  • Hemangioma of Infancy
  • hemangioma
  • Hemangioma



Children's National Medical Center Washington, District of Columbia  20010-2970